Inventor · disambiguated record
Christopher Semko
Also filed as: SEMKO CHRISTOPHER · SEMKO CHRISTOPHER M · SEMKO CHRISTOPHER M F · SEMKO CHRISTOPHER MICHAEL
65 granted patents·17 pending applications·835 citations·filing 1995–2025
99Inventor score
Files withELAN PHARM INC35REVOLUTION MEDICINES INC19WYETH CORP9ATHENA NEUROSCIENCES INC6KONRADI ANDREI W6
Top patents by PatentIndex Score
82 records- 0198US7049306B2Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4.ELAN PHARM INC·Filed 2002·Granted May 23, 2006·90 cites·6 claims
- 0295US12202845B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2022·Granted Jan 21, 2025·3 cites·6 claims
- 0395US11685749B2C26-linked rapamycin analogs as mTOR inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Jun 27, 2023·5 cites·8 claims
- 0495US10980889B1C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Apr 20, 2021·8 cites·6 claims
- 0594US12252497B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2022·Granted Mar 18, 2025·3 cites·10 claims
- 0694US12187746B2C26-linked rapamycin analogs as mTOR inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Granted Jan 7, 2025·5 cites·9 claims
- 0794US10590090B22,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2018·Granted Mar 17, 2020·28 cites·50 claims
- 0894US7427628B2Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrinsELAN PHARM INC·Filed 2006·Granted Sep 23, 2008·23 cites·14 claims
- 0994US6583139B1Compounds which inhibit leukocyte adhesion mediated by VLA-4Filed 2000·Granted Jun 24, 2003·56 cites·26 claims
- 1094US6479492B1Compounds which inhibit leukocyte adhesion mediated by VLA-4ELAN PHARM INC·Filed 2000·Granted Nov 12, 2002·41 cites·7 claims
- 1193US7008949B2Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrinsWYETH CORP·Filed 2003·Granted Mar 7, 2006·45 cites·16 claims
- 1293US6903088B2Compounds which inhibit leukocyte adhesion mediated by VLA-4WYETH CORP·Filed 2002·Granted Jun 7, 2005·31 cites·10 claims
- 1393US6794506B23-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4ELAN PHARM INC·Filed 2001·Granted Sep 21, 2004·30 cites·22 claims
- 1492US7026328B2Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrinsWYETH CORP·Filed 2003·Granted Apr 11, 2006·48 cites·18 claims
- 1592US7005433B2Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4ELAN PHARM INC·Filed 2003·Granted Feb 28, 2006·27 cites·9 claims
- 1690US7135477B2Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrinsELAN PHARM INC·Filed 2003·Granted Nov 14, 2006·28 cites·9 claims
- 1788US6689781B2Phenylalanine derivatives as alpha 4 integrin inhibitorsELAN PHARM INC·Filed 2001·Granted Feb 10, 2004·27 cites·9 claims
- 1887US7205310B2Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by VLA-4ELAN PHARM INC·Filed 2005·Granted Apr 17, 2007·11 cites·19 claims
- 1987US6900179B2Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4Filed 2001·Granted May 31, 2005·16 cites·13 claims
- 2086US7335663B2Heteroaryl compounds which inhibit leukocyte adhesion mediated by α4 integrinsELAN PHARM INC·Filed 2003·Granted Feb 26, 2008·19 cites·8 claims
- 2186US7229970B2Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4WYETH CORP·Filed 2005·Granted Jun 12, 2007·2 cites·11 claims
- 2286US6586602B2Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4Filed 2002·Granted Jul 1, 2003·10 cites·13 claims
- 2385US8030328B2Imidazolone phenylalanine derivativesELAN PHARM INC·Filed 2006·Granted Oct 4, 2011·10 cites·27 claims
- 2485US7973044B2Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4ELAN PHARM INC·Filed 2009·Granted Jul 5, 2011·4 cites·19 claims
- 2584US6492421B1Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4ATHENA NEUROSCIENCES INC·Filed 1998·Granted Dec 10, 2002·52 cites·35 claims
- 2683US7320960B2Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4ELAN PHARM INC·Filed 2002·Granted Jan 22, 2008·5 cites·20 claims
- 2783US6525026B2Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4ELAN PHARM INC·Filed 2001·Granted Feb 25, 2003·9 cites·18 claims
- 2882US7579466B2Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4ELAN PHARM INC·Filed 2007·Granted Aug 25, 2009·4 cites·32 claims
- 2981US7968547B2Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4ELAN PHARM INC·Filed 2009·Granted Jun 28, 2011·2 cites·10 claims
- 3081US7538215B2Compounds which inhibit leukocyte adhesion mediated by VLA-4ELAN PHARM INC·Filed 2005·Granted May 26, 2009·2 cites·4 claims
- 3181US6489300B1Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4Filed 1998·Granted Dec 3, 2002·40 cites·22 claims
- 3280US7576101B2Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agentsELAN PHARM INC·Filed 2004·Granted Aug 18, 2009·13 cites·26 claims
- 3380US7288526B2Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4WYETH CORP·Filed 2002·Granted Oct 30, 2007·5 cites·16 claims
- 3480US6953802B2Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4WYETH CORP·Filed 2001·Granted Oct 11, 2005·13 cites·28 claims
- 3578US7291645B2Phenylalanine derivatives as alpha 4 integrin inhibitorsELAN PHARM INC·Filed 2003·Granted Nov 6, 2007·7 cites·6 claims
- 3677US11673896B2Pyridine compounds as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2019·Granted Jun 13, 2023·1 cites·16 claims
- 3777US7754712B2Bridged N-cyclic sulfonamido inhibitors of gamma secretaseELAN PHARM INC·Filed 2007·Granted Jul 13, 2010·2 cites·27 claims
- 3876US8268935B2Preparation of polymer conjugates of therapeutic, agricultural, and food additive compoundsKONRADI ANDREI W·Filed 2006·Granted Sep 18, 2012·2 cites·41 claims
- 3976US7345056B2Bridged N-cyclic sulfonamido inhibitors of gamma secretaseELAN PHARM INC·Filed 2006·Granted Mar 18, 2008·2 cites·20 claims
- 4076US6291453B14-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4ATHENA NEUROSCIENCES INC·Filed 1998·Granted Sep 18, 2001·20 cites·32 claims
- 4176US2025074923A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 4276US2025361245A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 4375US11739093B2Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2019·Granted Aug 29, 2023·1 cites·18 claims
- 4475US7223762B2Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4WYETH CORP·Filed 2005·Granted May 29, 2007·2 cites·17 claims
- 4575US7015216B2Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitorsWYETH CORP·Filed 2001·Granted Mar 21, 2006·8 cites·10 claims
- 4675US2025051306A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 4774US8569426B2Preparation of polymer conjugates of therapeutic, agricultural, and food additive compoundsKONRADI ANDREI W·Filed 2012·Granted Oct 29, 2013·1 cites·8 claims
- 4874US7732609B25-(arylsulfonyl)-pyrazolopiperidinesELAN PHARM INC·Filed 2006·Granted Jun 8, 2010·2 cites·20 claims
- 4972US5858982ACathepsin and methods and compositions for inhibition thereofATHENA NEUROSCIENCES INC·Filed 1997·Granted Jan 12, 1999·20 cites·13 claims
- 5071US12365688B2Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Granted Jul 22, 2025·0 cites·36 claims
Showing the top 50 of 82 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Christopher Semko files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →